BD (Becton, Dickinson and Company) announced that Fresenius Kabi USA has acquired the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, N.C., and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes. BD and Fresenius Kabi have signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
234 USD | +1.45% | +4.55% | -4.01% |
Jul. 10 | Health Care Up in Anticipation of Deal Activity -- Health Care Roundup | DJ |
Jul. 10 | FDA Reports Supply Interruptions for Becton Dickinson BD BACTEC Culture Media Bottles | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.01% | 67.64B | |
-4.90% | 182B | |
-1.36% | 104B | |
-7.64% | 45.58B | |
+9.30% | 46.44B | |
+9.63% | 44.34B | |
+13.63% | 29.44B | |
+20.29% | 26.8B | |
-7.12% | 23.82B | |
+4.03% | 22.61B |
- Stock Market
- Equities
- BDX Stock
- News Becton, Dickinson and Company
- BD and Fresenius Kabi Announce Supply and Distribution Agreement